Fig 1: The role of the NDR1 inhibitor in reversing enzalutamide resistance in CRPC. A: Drug sensitivity profiling from the CellMiner database identifying candidate compounds negatively correlated with NDR1 expression. B: Western blot showing that 17AAG reduces AR and NDR1 expression in ENZR cells. C: Rescue experiment showing that NDR1 overexpression partially restores AR protein levels in HSP90-inhibited C4-2 cells. D: Western blot confirming that 17AAG reduces both endogenous and exogenous NDR1 protein expression. E-F: Colony formation (E) and EdU assays (F) showing reduced proliferation in C4-2 cells treated with enzalutamide and/or 17AAG (scale bar: 50 μm, n = 3). G: Flow cytometry revealing increased apoptosis after enzalutamide and/or 17AAG treatment in C4-2 cells (n = 3). H-I: Tumorsphere (H) and EdU (I) assays confirming that 17AAG alone reduces proliferation and tumorsphere formation in ENZR cells (scale bars: 150 μm in H, 50 μm in I, n = 3). J: Schematic illustration of the in vivo experimental workflow. K-L: Tumor images (K), body weights, and tumor volumes (L) showing that 17AAG inhibits tumor growth without affecting body weight in xenograft models (n = 5). M: H&E and IHC staining of xenograft tumors demonstrating decreased NDR1, AR, and USP9X expression upon 17AAG treatment (scale bar: 50 μm, n = 3). Error bars represent mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.